Downgrades Outperform Mkt Perform X

APLT Applied Therapeutics

William Blair

Downgrades Buy Neutral X

APLT Applied Therapeutics

UBS

$13 $2

Downgrades Outperform Sec Perform X

APLT Applied Therapeutics

RBC Capital Mkts

$12 $4

Initiated Outperform X

APLT Applied Therapeutics

William Blair

Initiated Outperform X

APLT Applied Therapeutics

RBC Capital Mkts

$12

Initiated Outperform X

APLT Applied Therapeutics

Leerink Partners

$12

Downgrades Overweight Eq Weight X

APLT Applied Therapeutics

Barclays

$44 $7

Resumed Neutral X

APLT Applied Therapeutics

Goldman

$18

Initiated Buy X

APLT Applied Therapeutics

Citigroup

$29

Initiated Outperform X

APLT Applied Therapeutics

Cowen

Initiated Outperform X

APLT Applied Therapeutics

Robert W. Baird

$24

APLT  Applied Therapeutics, Inc.

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.